MedTrace Logo

Uncertainty About the Benefits of New Cancer Drugs and Patients' Treatment Preferences

NCT07694310 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3000

Last updated 2026-08-04

No results posted yet for this study

Summary

This study of current or former cancer patients will evaluate the effect of learning about uncertainties with the benefits of a new cancer drug on their hypothetical decisions to take the drug and their perceptions of the drug's effectiveness.

Conditions

Interventions

OTHER

Control

No uncertainty information

OTHER

Unvalidates surrogate endpoint

Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.

OTHER

Limited study population

Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.

OTHER

Small magnitude of effect

It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.

OTHER

Multiple uncertainties

All 3 statements shown above

Sponsors & Collaborators

  • Harvard Medical School and Harvard Pilgrim Health Care Institute

    collaborator UNKNOWN

  • London School of Economics and Political Science

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-14
Primary Completion
2026-10-01
Completion
2026-10-01

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07694310 on ClinicalTrials.gov